The Official MicroCap News Source
Watchlist News
Please Login or Register to view News Stories

Healthcare & Insurance

NEOVACS ANNOUNCES THE APPOINTMENT of Dr. VIRGINIA PASCUAL AS MEDICAL AND SCIENTIFIC ADVISOR

PRESS RELEASE · PRESS RELEASE  · PRESS RELEASE NEOVACS ANNOUNCES THE APPOINTMENT ofDr. VIRGINIA PASCUAL AS MEDICAL AND SCIENTIFIC ADVISOR Paris and Boston, June 27th, 2019 – Neovacs – 7:30 am CEST - (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the

Thursday, June 27, 2019

Sanofi : FDA to review MenQuadfi, a meningococcal vaccine candidate

                                                                                                                                                            FDA to review MenQuadfiTM 1, a meningococcal vaccine candidate

Thursday, June 27, 2019

Bone Therapeutics SA to raise capital through private placement of new shares and issuance of non-dilutive subordinated bonds

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO PRESS RELEASEREGULATED INFORMATION - INSIDE INFORMATION Gosselies,

Thursday, June 27, 2019

Atlas Nanotech of Guadalajara to begin alliance with European Nano Medical S.R.O.

GUADALAJARA, Mexico, June 27, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – CSSI (Costas Inc.) DBA Atlas Nanotech has entered an accord with Nano Medical S.R.O. of the Czech Republic. The first objective of the accord aims to establish distribution in new territories for both companies. A most

Thursday, June 27, 2019

BridgeBio Pharma Announces Pricing of Its Initial Public Offering

PALO ALTO, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) today announced the pricing of its initial public offering of 20,500,000 shares of its common stock at a price to the public of $17.00 per share, above the range of $14.00 to $16.00. In addition,

Thursday, June 27, 2019

Adaptive Biotechnologies Announces Pricing of Initial Public Offering

SEATTLE, June 26, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to improve patient

Wednesday, June 26, 2019

Ascent Industries Provides Update From Special General Meeting

VANCOUVER, British Columbia, June 26, 2019 (GLOBE NEWSWIRE) -- Ascent Industries Corp. (CSE: ASNT) (“Ascent” or the “Company”) today announced that all resolutions were passed by the requisite majority at its special general meeting (“SGM”) held in Vancouver, British Columbia on June

Wednesday, June 26, 2019

ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC

LYON, France and CAMBRIDGE, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first patient has been

Wednesday, June 26, 2019

OraSure Technologies and Others Join Forces for HIV Testing Day

Free HIV tests will be available across the country to spread awareness for National HIV Testing Day on June 27.BETHLEHEM, Pa., June 26, 2019 (GLOBE NEWSWIRE) -- National HIV Testing Day will be commemorated on June 27 across the nation with efforts to raise awareness of HIV and encourage people

Wednesday, June 26, 2019

Forward Pharma A/S Announces Intention to Transfer its U.S. Public Listing to the Nasdaq Capital Market Stock Exchange

COPENHAGEN, Denmark, June 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced its intention to transfer its public listing of American Depositary Shares from the Nasdaq Global Select Market to the Nasdaq Capital Market. This follows the development in

Wednesday, June 26, 2019

Harvard Bioscience Subsidiary Data Sciences International Launches Hardware for Expanding Research Capabilities

Designed to Acquire and Synchronize Pre-clinical Signals from Disparate SourcesST. PAUL, Minn. and HOLLISTON, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc. (Nasdaq: HBIO) and the global leader in wireless physiologic

Wednesday, June 26, 2019

VIVUS and Nordmark Amend Contract Manufacturing Agreement to Supply Current and Future Demand for PANCREAZE®

-Companies will also collaborate to develop additional PANCREAZE dose formulations and an advanced formulation with an extended shelf life- CAMPBELL, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced an amendment to

Wednesday, June 26, 2019

FedNat Announces Mel Russell to Join the Leadership Team at Monarch National Insurance Company

SUNRISE, Fla., June 26, 2019 (GLOBE NEWSWIRE) -- FedNat Holding Company (NASDAQ: FNHC), an insurance holding company, today announced the appointment of Mel Russell to Vice President at Monarch National Insurance Company, its wholly-owned subsidiary. Mr. Russell will lead Monarch, starting with

Wednesday, June 26, 2019

Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts

51% of subjects in Cohort 2 achieved complete clearance of all treatable warts VP-102 was well-tolerated with no serious adverse events reported Common warts affect approximately 22 million people in the United States Based on positive outcome, Verrica to request an ‘End of Phase 2’ meeting

Wednesday, June 26, 2019

Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints

ATI-502 did not achieve statistical superiority at the primary or secondary endpoints due to high rates of disease resolution in vehicle-treated patients WAYNE, Pa., June 26, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on

Wednesday, June 26, 2019

American National named to Forbes’ 2019 “Best Mid-size Employers” list

GALVESTON, Texas, June 26, 2019 (GLOBE NEWSWIRE) -- American National Insurance Company has been recognized by Forbes as one of America’s Best Mid-Size Employers. Forbes selected the companies based on an independent survey of U.S employees. “I’m pleased American National has been

Wednesday, June 26, 2019

Changes to the financial calendar 2018/19

Company announcement No 09/2019 Attachment No 09 2019_Changes to Financial Calendar 2018_2019

Wednesday, June 26, 2019

Interim Report September 1, 2018 - May 31, 2019

Company Announcement No 08, 2019 Solid sales growth and profitability in Q3, but reduced organic growth outlook for the year. Attachment No 08 2019 Company announcement Q3 FY19

Wednesday, June 26, 2019

Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis

FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP) Dupixent significantly reduces nasal polyp size, improves congestion and loss of smell, while

Wednesday, June 26, 2019

AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease

Paris, June 26, 2019, 7pm Interim results of masitinib study in Alzheimer’s disease:positive trend of efficacy in one of the doses tested Final analysis will be available in Q4 2019 AB Science SA (NYSE Euronext - FR0010557264 - AB) reports the outcome from the interim analysis of study AB09004

Wednesday, June 26, 2019

loading

© 2019 Stock News Now